$High-density lipoprotein subfractions - What the clinicians need to know$
QR Code

QR Code

High-density lipoprotein subfractions - What the clinicians need to know

Copyright © 2013 S. Karger AG, Basel. Although the inverse relationship between plasma levels of high-density lipoprotein (HDL) and cardiovascular disease has been largely demonstrated, many observations have suggested that the assessment of HDL functionality might be more informative than a simple...

Full description

Bibliographic Details
Main Authors:	Pirillo, A., Norata, Giuseppe, Catapano, A.
Format:	Journal Article
Published:	2013
Online Access:	http://hdl.handle.net/20.500.11937/56370

Similar Items

Treating high density lipoprotein cholesterol (HDL-C): Quantity versus quality
by: Pirillo, A., et al.
Published: (2013)

Emerging role of high density lipoproteins as a player in the immune system
by: Norata, Giuseppe, et al.
Published: (2012)

High density lipoproteins and atherosclerosis: Emerging aspects
by: Sala, F., et al.
Published: (2012)

Vascular inflammation and low-density lipoproteins: Is cholesterol the link? A lesson from the clinical trials
by: Catapano, A., et al.
Published: (2017)

Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering
by: Norata, Giuseppe, et al.
Published: (2016)

The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis
by: Pirillo, A., et al.
Published: (2018)

Association of backfat thickness with postheparin lipoprotein lipase activity and very low density lipoprotein-subfractions in growing pigs
by: Loh, Teck Chwen, et al.
Published: (2001)

Relationships of plasma and very low density lipoprotein lipids and subfractions with abdominal fat in chickens
by: Loh, Teck Chwen, et al.
Published: (2011)

Characterisation of low density lipoprotein subfraction profile and apoe genotype among diabetic patients
by: Bebakar, Wan Mohamad Wan
Published: (2001)

The missing link between high-density lipoprotein cholesterol and inflammatory response in cardiovascular disease
by: Ammirati, E., et al.
Published: (2014)

High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease
by: Baragetti, A., et al.
Published: (2013)

MicroRNAs and lipoproteins: A connection beyond atherosclerosis?
by: Norata, Giuseppe, et al.
Published: (2013)

Perfectionism in obsessive-compulsive disorder and related disorders: What should treating clinicians know?
by: Pinto, A., et al.
Published: (2017)

PCSK9 inhibition in statin-intolerant HeFH patients: What's new?
by: Casula, M., et al.
Published: (2017)

Refugee Resettlement in Australia: What we know and need to know
by: Fozdar, F., et al.
Published: (2013)

Faecal immunochemical tests versus guaiac faecal occult blood tests: What clinicians and colorectal cancer screening programme organisers need to know
by: Tinmouth, J., et al.
Published: (2015)

What You Need to Know about the PDPA
by: Zulhuda, Sonny
Published: (2012)

LOX-1, OxLDL, and atherosclerosis
by: Pirillo, A., et al.
Published: (2013)

Postprandial lipemia as a cardiometabolic risk factor
by: Pirillo, A., et al.
Published: (2014)

Therapy and clinical trials: Aggressive statin therapy versus combined and emerging approaches
by: Catapano, A., et al.
Published: (2011)

Niemann-pick C1-like 1 (NPC1L1) inhibition and cardiovascular diseases
by: Pirillo, A., et al.
Published: (2016)

HDLs, immunity, and atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2011)

HDL in infectious diseases and sepsis
by: Pirillo, A., et al.
Published: (2015)

Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?
by: Catapano, A., et al.
Published: (2017)

Strategies for the use of nonstatin therapies
by: Pirillo, A., et al.
Published: (2017)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives
by: Catapano, A., et al.
Published: (2017)

Leaders debate the GST: What you need to know
by: Grattan, M., et al.
Published: (2015)

Apolipoprotein C-III: From Pathophysiology to Pharmacology
by: Norata, Giuseppe, et al.
Published: (2015)

Omega-3 fatty acids. What consumers need to know
by: McManus, Alexandra, et al.
Published: (2010)

A study of the relationship between apo E genotypes and transitions of HDL subfractions in uncomplicated diabetes mellitus type 2, and the effect of various anticoagulants on lipoprotein levels.
by: Rashid, Faridah Abdul
Published: (2004)

HDL: To treat or not to treat?
by: Pirillo, A., et al.
Published: (2014)

HDL in innate and adaptive immunity
by: Catapano, A., et al.
Published: (2014)

Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps
by: Baragetti, A., et al.
Published: (2018)

The turtles of tropical asia : what we know, what we don't know and what we think we know
by: Das, I.
Published: (2005)

The structure and dynamics of plasma high-density lipoproteins and their interactions with the beta-amyloid peptide
by: Malajczuk, Chris
Published: (2022)

SYDNEY NALOXONE DISTRIBUTION PROGRAM - WHAT CLINICIANS AND CLIENTS THINK
by: Ivan, M., et al.
Published: (2012)

"You can't ask questions about what you don't know". Determing the needs of patients with high grade gliomas and their carers
by: Halkett, Georgia, et al.
Published: (2007)

Oxidizes Low Density Lipoprotein Cytoxicity and Vascular Diseases
by: Gieseg, Steven P., et al.
Published: (2009)

Differentiating knowledge transfer and technology transfer: What should an organizational manager need to know?
by: Ismail, Maimunah, et al.
Published: (2018)

Occupational Safety and Health Legislation: What Allied Health Professionals in Western Australia Need to Know
by: Brown, Kevin
Published: (2003)

Cannot write session to /tmp/vufind_sessions/sess_c6hi9g5ps6nss6a05tnehbbopf